Superworth

Arbutus Biopharma ABUS

Drug Manufacturers - General, Healthcare
$4.00
−4.99%
Market cap
$791.4M
PE
5.1×
Forward PE
n/m
not a meaningful number
Price to sales
4.4×
EV/EBIT
4.7×
Revenue, 12 months
$181.7M
growth n/m, growth from a base too small to compare
Net margin
84.2%
Free cash flow yield
n/m
not a meaningful number

Arbutus Biopharma trades at 5.1× trailing earnings. Revenue was $181.7M over the last twelve months with a 84% net margin.

Charts

Financials

Income statement for ABUS, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$4.7M−22%$2.1M−66%$1.5M−77%$1.7M−63%$1.3M−71%$1.6M−27%$1.8M+15%$10.7M+522%$529K−61%$1.1M−33%$179.1M+10055%$1M−91%
R&D$20.2M+1%$17.6M−24%$15.4M−16%$15.6M−12%$14.3M−29%$8.8M−50%$9M−42%$5.5M−65%$5.8M−60%$5M−43%$4.1M−54%$2.9M−47%
SG&A$5.8M+67%$5.1M+20%$5.3M−4%$7.5M+26%$4.5M−22%$4.7M−8%$5.8M+10%$3.3M−56%$3M−33%$3.7M−22%$5.9M+1%$3.9M+16%
−$21.6M+21%−$20.7M−8%−$19.4M+11%−$21.6M+17%−$21.4M−1%−$13.9M−33%−$25.7M+33%$1.5M−$8.7M−60%−$5.3M−62%$168.9M−$6M
Interest expense$46K−89%$44K−86%$44K−78%$34K−80%$29K−37%$30K−32%$28K−36%$28K−18%$23K−21%$18K−40%$17K−39%$18K−36%
Pre-tax income−$20.1M+14%−$19.3M−12%n/an/an/an/an/an/an/an/an/an/a
$0$0n/an/an/an/an/an/an/an/an/an/a
Net income−$20.1M+14%−$19.3M−12%−$17.9M+9%−$19.8M+16%−$19.7M−2%−$12.5M−35%−$24.5M+37%$2.5M−$7.7M−61%−$3.8M−70%$169.7M−$5.1M
−$0.12+0%−$0.11−21%−$0.10+0%−$0.11+10%−$0.10−17%−$0.07−36%−$0.13+30%$0.01−$0.04−60%−$0.02−71%$0.87−$0.03
167.5M+11%168.6M+8%175.6M+9%188M+13%189M+13%189.7M+13%190.7M+9%192.4M+2%191.8M+2%192.3M+1%195.2M+2%197.5M+3%

Net income: Q2 FY18: not printed by the filing, worked out from its own lines.

EPS, diluted: 12 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 13 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Arbutus Biopharma's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
Peer median$685.3M13.8×17.0×1.6×+10%11.2%

More on Arbutus Biopharma

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .